Coronary Angiography in patients with worsening heart failure: Determinants, Findings, and Prognostic Implications

João Pedro Ferreira, MD, PhD¹,²; Patrick Rossignol, MD, PhD¹; Biniyam Demissei, MD, PhD³; Abhinav Sharma, MD⁴,⁵; Nicolas Girerd, MD, PhD¹; Stefan D. Anker, MD, PhD⁶; John G. Cleland, MD, PhD⁷; Kenneth Dickstein, MD, PhD⁸,⁹; Gerasimos Filippatos, MD, PhD¹⁰; Hans L. Hillegä, MD, PhD¹¹; Chim C. Lang, MD¹¹; Marco Metra, MD¹²; Leong L. Ng, MD¹³; Piotr Ponikowski, MD, PhD¹⁴; Nilesh J. Samani, MD, PhD¹⁵; Dirk J. van Veldhuisen, MD; PhD¹; Aeikko H. Zwinderman, Ph¹⁶; Adriaan Voors, MD, PhD¹; Faiez Zannad, MD, PhD¹

Affiliations:
¹ INSERM, Centre d'Investigations Cliniques Plurithématique 1433, Université de Lorraine, CHRU de Nancy and F-CRIN INI-CRCT, Nancy, France.
² Cardiovascular Research and Development Unit, Department of Physiology and Cardiothoracic Surgery, Faculty of Medicine, University of Porto, Portugal.
³ Department of Cardiology, University of Groningen, University Medical Center Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands.
⁴ Duke Clinical Research Institute, Duke University, Durham, North Carolina.
⁵ Mazankowski Alberta Heart Institute, University of Alberta, Edmonton, Alberta, Canada.
⁶ Department of Innovative Clinical Trials, University Medical Centre Göttingen (UMG), Robert-Koch-Straße, D-37075, Göttingen, Germany.
⁷ Robertson Centre for Biostatistics and Glasgow Clinical Trials Unit, Glasgow, UK.
⁸ University of Bergen, Bergen, Norway.
⁹ Stavanger University Hospital, Stavanger, Norway.
¹⁰ National and Kopodistrian University of Athens, School of Medicine, Heart Failure Unit, Department of Cardiology, Athens University Hospital Attikon, Rimini 1, Athens 12462, Greece.
¹¹ Division of Molecular and Clinical Medicine, Ninewells Hospital and Medical School, University of Dundee, Dundee, UK.
¹² University of Brescia, Italy
¹³ Department of Cardiovascular Sciences, University of Leicester, Leicester, United Kingdom; Cardiovascular theme, NIHR Leicester Biomedical Research Centre, Glenfield Hospital, Leicester, LE3 9QP, United Kingdom
¹⁴ Department of Cardiology, Centre for Heart Diseases, 4th Military Hospital, Wroclaw, Poland; Department of Heart Diseases, Wroclaw Medical University, Wroclaw, Poland.
¹⁵ Department of Cardiovascular Sciences, University of Leicester, BHF Cardiovascular Research Centre, Glenfield Hospital, Groby Rd, Leicester, LE3 9QP, United Kingdom
16 Academic Medical Center, Clinical Epidemiology Biostatistics and Bioinformatics, Amsterdam, Netherlands

**Corresponding author:**
Professor Faiez Zannad
Centre d'Investigation Clinique Inserm, CHU, Université de Lorraine.
Institut Lorrain du Coeur et des Vaisseaux
4, rue du Morvan, 54500 VANDOEUVRE-LES-NANCY
Mail to: f.zannad@chru-nancy.fr

Word-count: 2501 words (excluding abstract and references)
Abstract

Introduction: Coronary angiography is regularly performed in patients with worsening signs and/or symptoms of heart failure (HF). However, little is known on the determinants, findings, and associated clinical outcomes of coronary angiography performed in patients with worsening heart failure.

Methods: The BIOSTAT-CHF (A systems BIOlogy Study to TAIlored Treatment in Chronic Heart Failure) program enrolled 2516 patients with worsening symptoms and/or signs of HF, either hospitalized or in the out-patient setting. All patients were included in the present analysis.

Results: Of the 2516 patients included, 315 (12.5%) underwent coronary angiography within the 30 days after the onset of worsening symptoms and/or signs of heart failure. Subjects who underwent angiography were more often observed as inpatients, had more often an overt acute coronary syndrome, had higher troponin I levels, were younger, and had better renal function (all \( p \leq 0.01 \)). Patients who underwent coronary angiography had a lower risk of the primary outcome of death and/or HF hospitalization (adjusted HR=0.71, 95%CI=0.57-0.89; \( p = 0.003 \)) and death (adjusted HR=0.59, 95%CI=0.43-0.80, \( p = 0.001 \)). Among the patients who underwent coronary angiography, those with a coronary stenosis (39%) had a worse prognosis than those without stenosis (adjusted HR for the primary outcome=1.71, 95%CI=1.10-2.64, \( p = 0.016 \)).

Conclusions: Coronary angiography was performed in <13% of patients with symptoms and/or signs of worsening heart failure. These patients were remarkable different from those that did not undergo coronary angiography and had a lower risk of subsequent events. The presence of coronary stenosis on coronary angiography was associated with a worse prognosis.

Key-words: Decompensated Heart Failure; Coronary Angiography; Myocardial Infarction; Outcomes
**Introduction**

Coronary angiography is the “gold standard” technique for the assessment of the presence and the extension/severity of coronary artery disease, and to define the most appropriate therapy. Current heart failure guidelines state that coronary angiography is recommended for the determination of heart failure (HF) etiology, especially in patients who suffer from angina pectoris, those with a history of ventricular arrhythmia or aborted cardiac arrest, and in patients with and intermediate to high pre-test probability of coronary artery disease, which includes a “positive” non-invasive stress test.

In patients with worsening symptoms and/or signs of heart failure, coronary angiography may be infrequently performed, regardless of hospitalization or ambulatory status. However, little is known about the type of patients that undergo coronary angiography, whether significant coronary artery disease if found, and whether it has prognostic implications.

The aims of the present analysis are to assess: 1) related factors and characteristics of patients with worsening heart failure who undergo coronary angiography; 2) the findings of coronary angiography regarding the presence of coronary stenosis; 3) the prognostic value of coronary angiography and coronary stenosis.

**Methods**

**Patient population**

BIOSTAT-CHF is a European project that enrolled 2516 HF patients from 69 centres in 11 European countries to determine profiles of patients with HF that do not respond to recommended therapies, despite anticipated up-titration. The design and first results of the study and patients have been described elsewhere. In brief, patients were aged ≥18 years with symptoms of new-onset or worsening HF, confirmed either by a left ventricular ejection fraction (LVEF) of ≤40% or a BNP and/or NT-proBNP plasma levels >400 pg/ml or >2000pg/ml, respectively. Patients needed to be treated with either oral or intravenous furosemide ≥40 mg/day or equivalent at the time of inclusion. Patients should not have been previously treated with evidence based therapies (ACEi/ARBs and β-blockers) or were receiving <50% of the target doses of at least one of these drugs at the time of inclusion. Initiation or up-titration of ACEi/ARB and/or β-blocker therapy should have been anticipated by the treating physician. The first three months of treatment were considered to be the optimization phase after which a stabilization phase of 6 months was defined. During the optimization phase, initiation or up-titration of ACEi/ARB and/or β-blocker was performed according to the routine clinical practice of the treating physicians, who were encouraged to follow the ESC guidelines at the time of treatment. Patients with acute coronary syndrome or stroke could be included when the primary diagnosis for admission to hospital or outpatient clinic visit was heart failure. The
The recruitment period was 24 months, starting from December 2010. The last patient was included on December 15, 2012. Median follow-up was 21 months.

In the present analysis, we included all coronary angiographies performed within 30 days after the baseline visit, because coronary angiography could have been done as “programmed intervention” and, therefore, a time gap between the intervention and the baseline visit was expected. Coronary stenosis was defined as >50% luminal stenosis.

**Statistical analysis**

In descriptive analyses, continuous variables are expressed as mean ± standard deviation (SD). Categorical variables are expressed as frequencies and proportions (%). Population description and comparison of patients with coronary angiography vs. no coronary angiography performed (and coronary artery coronary stenosis vs. no stenosis) was performed using independent samples t-test for normally distributed continuous variables, Mann-Whitney test for continuous variables with a skewed distribution, and chi-square test for categorical variables. Normality assumptions were verified by visual inspection. No multiple imputation was performed.

To determine the factors associated with having a coronary angiography performed (or not) and to having a coronary artery coronary stenosis (or not), we developed logistic regression models. These models used clinical and laboratory variables with a p-value <0.1 as entry criteria (from Table 1). Logistic regression assumptions were checked and multicollinearity excluded. Linear relationship between continuous independent variables and the logit transformation of the dependent variable was verified by plotting the means vs. the β estimates in quintiles (Supplemental Figure 1). If a linear relationship was not present, then the variable was dichotomized at the inflexion point. Then a stepwise backward selection process was applied and the final model presented.

Cox proportional hazard regression models were used to model long-term event rate both in univariable and multivariable analysis. Cox models’ assumptions were verified. In the multivariable models, the covariates for adjustment were chosen from demographic (age and gender), clinical (previous HF hospitalization, use of beta-blockers and systolic blood pressure), and laboratory (NT-proBNP, blood urea nitrogen, hemoglobin, HDL-cholesterol, creatinine, sodium). All parameters were previously found to be independently associated with the outcomes in the BIOSTAT cohort and were used to build the risk models derived from this cohort (URL: https://biostat-chf.shinyapps.io/calc/). The primary outcome was a composite of hospitalization for heart failure and all-cause death. The outcomes of HF hospitalization and death were also analyzed separately.

The adjudication of events (heart failure hospitalizations) were done by the treating physician.

All the analysis was performed using R® software (R Core Team, 2013. R: A language
Results

Characteristic of the study population

From the 2516 patients included in BIOSTAT-CHF, 12.5% (n=315) underwent coronary angiography.

Characteristics of patients with or without coronary angiography are presented in Table 1. Patients who underwent coronary angiography more often presented as inpatients, with an acute coronary syndrome (ACS), were younger, had higher heart rate, hemoglobin, estimated glomerular filtration rate (eGFR), alanine/aspartate aminotransferase (ALAT/ASAT) and troponin I levels. The troponin I threshold for coronary angiography performance was high: only patients in the highest troponin quintile (>36 ng/dL) were more likely to have a coronary angiogram performed. Supplemental Figure 1. Nonetheless, troponin I levels were linear and independently associated with dismal prognosis in this population and added prognostic information to the BIOSTAT risk models. Supplemental Table 2 and Supplemental Table 3. Patients who underwent coronary angiography were also more often smokers and more frequently treated with ACEi/ARBs, had lower LVEF, urea, and potassium, were less often hospitalized in the year before baseline visit, had ischemic cardiopathy less often documented, had lower proportion of atrial fibrillation, previous stroke, device therapy, and previous coronary intervention (p <0.01 for all). Table 1. Country subanalysis shows that the Netherlands, France and Germany had the higher proportion of patients undergoing coronary angiography, and the Netherlands contributed to more than 25% of all angiographies performed. Supplemental Table 4.

Independent predictors for performing a coronary angiography are presented in Table 2. The strongest independent predictors of undergoing coronary angiography were an in-hospital visit (Odds Ratio, OR =11.6, 95% Confidence Interval, CI =4.6-28.8, p <0.0001), overt acute coronary syndrome (OR =3.1, 95%CI =1.9-5.0, p <0.0001), troponin I levels above 36 pg/mL (OR =1.6, 95%CI =1.1-2.3, p =0.011), a younger age (OR per each decade less = 1.4, 95%CI =1.2-1.6, p <0.0001), and better renal function (OR per 10 ml/min/1.73m² increase in eGFR =1.1, 95%CI =1.0-1.2, p =0.049). Patients with a cardiac device, those with previous HF hospitalization and those with previous coronary intervention were less likely to have a coronary angiography performed. Table 2.

Coronary angiographic findings

A coronary stenosis (>50% luminal stenosis) was found in 38.7% (n=122) of the 315 patients who underwent coronary angiography. Characteristics of patients with and without a
coronary stenosis are presented in the Supplementary Table 1. Patients with a coronary stenosis were older, more often male, smokers, and hypertensive, had higher proportion of pulmonary rales, HF of ischemic etiology more often documented, higher troponin I levels, and higher proportion of previous coronary intervention (p <0.01 for all).

Among the patients who underwent coronary angiography, those with HF of ischemic etiology (OR =33.4, 95%CI =16.4-68.0, p <0.0001) and with higher troponin I levels (OR per 1 log increase =1.3, 95%CI =1.0-1.7, p =0.026) were more likely to have a coronary coronary stenosis. Table 3.

Prognostic implications of coronary angiography and presence of coronary stenosis

Patients who underwent coronary angiography had a better clinical outcome compared to those who did not undergo coronary angiography (adjusted Hazard Ratio, HR for the primary composite outcome of death and/or heart failure hospitalization =0.71, 95%CI =0.57-0.89, p =0.003 and HR =0.59, 95%CI =0.43-0.80, p =0.001 for the outcome of death). Table 4. Among the patients who underwent coronary angiography, those with a coronary stenosis had worse prognosis (adjusted HR for the primary composite outcome of death and/or heart failure hospitalization =1.71, 95%CI =1.10-2.64, p =0.016 and HR =2.09, 95%CI =1.10-3.96, p =0.024). Table 4.

A significant interaction between HF etiology (ischemic vs. other) and coronary angiography (yes vs. no) was found. Patients who underwent coronary angiography with non-ischemic HF had a greater reduction of the primary composite outcome (HR =0.55, 95%CI =0.40-0.76, p <0.001) than patients who underwent coronary angiography with ischemic heart failure (HR =1.00, 95%CI =0.74-1.37, p =0.98; p for interaction =0.007. Figure 1 and Figure 2.

Patients that underwent coronary angiography also had their ACEi/ARBs more frequently up-titrated. Supplemental Table 2.

Discussion

The present study shows that ≈13% of patients with worsening HF underwent a coronary angiography within 30 days after the onset of worsening symptoms and/or signs of HF. In general, these patients had a better clinical profile and outcome than those who did not undergo coronary angiography. However, patients with a coronary stenosis on coronary angiography had a worse prognosis compared to those without a coronary stenosis.

In our study, the coronary angiography rate was higher than in previous reports where less than 10% of the patients with worsening HF underwent coronary angiography. Nonetheless, in patients with decompensated HF, coronary artery disease may be the primary HF etiology in more than 50% of the patients. Hence, aiming coronary artery disease as a therapeutic target in worsening HF (even without overt ACS) may be associated with
improved clinical outcome, and although a causal relation cannot be inferred, recurrent ischemic events are a major cause of subsequent HF decompensation and death^{12}.

In the present report, only 23% (n=54) of the subjects presenting with an overt ACS (n=155) underwent coronary angiography within the worsening HF episode (±30 days). These data suggest that the large majority of the coronary angiographies were performed in patients with other primary causes for HF decompensation. Hence, in the present study physicians possibly decided to perform a coronary angiography based on the suspicion that an underlying coronary artery disease was a major contributor for worsening HF signs and/or symptoms supported by particularly high troponin threshold for angiography performance. Troponin elevation is frequently observed in patients with decompensated HF, possibly reflecting myocardial injury and/or impaired myocardial perfusion, and has been associated with worse prognosis^{13}. While doctors acknowledge troponin elevation as part of the decompensation episode, they may withhold coronary angiography unless very high troponin levels are found, because despite the myocardial injury, patients with decompensated HF may have a predominance of respiratory symptoms, high prevalence of diabetes, and use medications such as nitrates, beta-blockers, and ivabradine that may blunt “typical” angina pectoris symptoms^{14, 15}.

Diagnostic procedures may influence treatment decisions (directly and/or indirectly) and consequently prognosis^{16-18}. In this context, the performance of a coronary angiography may provide information regarding the extent/severity of coronary artery disease and also provide an opportunity for direct intervention (e.g., coronary revascularization) that will likely have influence on the follow-up, treatment and prognosis of these patients^{14, 19}. In the present study performing a coronary angiography was associated with improved outcomes, finding that is consistent with the OPTIMIZE-HF registry^{10}, however no causality can be established as this may reflect only selection bias and better baseline patient profile.

Older patients and those with worse renal function were less likely to have a coronary angiography performed. It has been thoroughly documented that elderly patients and those with impaired renal function presenting with an ACS and/or acute HF undergo substantially less angiographic/revascularization procedures, despite deriving similar relative benefits of these interventions^{10, 20, 21}. Remarkably, coronary angiography was not less likely to be performed in females, even though females in this study were older. Patients with cardiac devices, previous coronary interventions and HF hospitalization, and those observed as outpatients were less likely to undergo coronary angiography. These findings may be due to the assumption that the patients were already investigated for coronary disease at the timing of device implantation or that those presenting as outpatients may have less severe symptomatology and require less investigation. Nevertheless, these patients may be at higher risk for myocardial ischemia and stent restenosis^{22}. 
We found an “interaction” between HF etiology (ischemic vs. other) and the prognostic value of coronary angiography. Performing a coronary angiography in patients without previously known ischemic etiology was associated with a better outcome than in patients with documented HF of ischemic etiology, possibly because it may allow the assessment of coronary artery disease that would otherwise pass untreated\textsuperscript{23}.

Patients who underwent coronary angiography and had coronary stenosis documented (\(\approx 39\%\) in the present cohort) had worse prognosis compared to those without coronary stenosis. The presence of significant coronary lesions is associated with dismal prognosis, as also documented in previous reports\textsuperscript{24}.

**Clinical and Research Implications**

The present results show that coronary angiography was performed in <13\% of patients with worsening HF. These subjects were younger and with a more favorable overall clinical profile. Therefore, these data should be taken as merely descriptive and no causality should be inferred from these observations. From a research standpoint, a trial comparing “usual care” versus an arm with a low threshold for coronary angiography could provide more definitive answers on the diagnostic and prognostic abilities of this intervention.

**Limitations**

Several limitations should be noticed in this study. First, this is a secondary analysis of a prospective non-randomized observational study, therefore all limitations inherent to such analysis are applied herein, including the inability to infer causality. Additionally, it is likely that unmeasured variables may have contributed for the different outcomes observed. Second, this study was not designed to address coronary angiography performance, however these data may reflect “real-world” practices as no guidance was provided with regard to coronary interventions. Third, it is also impossible to account for the effect of selection biases that may have determined who underwent angiography as well as treatment biases that may have influenced whom received pharmacological therapies for coronary artery disease and HF. Fourth, results from stress testing and coronary intervention outcomes (e.g., stent placement, coronary artery bypass grafting referral) are not available. Fifth, the participating hospitals in the BIOSTAT-CHF differed in structure (from tertiary university hospitals to small non-academic structures) and likely in the access to a catheterization laboratory, hence these findings cannot be generalized to all hospitals and HF patients. However, further adjustment for the type of centre did not change the strength of the associations. Sixth, we can only hypothesize on the reasons that led clinicians to perform a coronary angiogram since this information is also not available. Lastly, the data from the BIOSTAT-CHF come from European centres only and may not be representative of HF patients in other world regions.
Conclusions

Coronary angiography was performed in <13% of patients with symptoms and/or signs of worsening heart failure, particularly those presenting as inpatients, with an acute coronary syndrome, with better renal function and younger age. Performing a coronary angiogram was associated with improved outcomes but this observation possibly reflects a selection bias.

Acknowledgements/Funding

This project was funded by a grant from the European Commission (FP7-242209-BIOSTAT-CHF; EudraCT 2010–020808–29).

Disclosures

J.P.F. has received board membership fees from Novartis. A.A.V reports consultancy fees and/or research grants from: Alere, Amgen, Bayer, Boehringer Ingelheim, Cardio3Biosciences, Celladon, GSK, Merck/MSD, Novartis, Servier, Stealth Peptides, Singulex, Sphingotec, Trevena, Vifor, and ZS Pharma. S.A. Anker reports grants from Vifor and Abbott Vascular, and fees for consultancy from Vifor, Bayer, Boehringer Ingelheim, Brahms, Cardiorentis, Janssen, Novartis, Relypsa, Servier, Stealth Peptides, and ZS Pharma. K.D. has received honoraria and/or research support from Medtronic, Boston Scientific St Jude, Biotronik and Sorin (device companies), and Merck, Novartis, Amgen, Boehringer Ingelheim, Astra Zeneca, Pfizer, Bayer, GSK, Roche, Sanofi, Abbott, Otsuka, Leo, Servier, and Bristol Meyers Squibb (pharmaceutical companies). G.F. has received fees and/or research grants from Novartis, Bayer, Cardiorentis, Vifor, Servier, Alere, and Abbott. P.vdH. received a research grant from Abbott. C.L. received consultancy fees and/or research grants from Amgen, Astra Zeneca, MSD, Novartis, and Servier. D.vV. reports membership fees/travel expenses from Johnson & Johnson, Novartis, Vifor, and Corvia Medical. M.M. has received consulting honoraria from Amgen, Bayer, Novartis, and Servier, and speaker’s fees from Abbott Vascular, Bayer, and ResMed. All other authors refer that they have no relevant conflicts of interest to disclose related to the present manuscript.

Bibliography


collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 2008, 29 (19), 2388-442.


